Astra Tech's OsseoSpeed TX implant line launched to the US market at AO Annual Meeting

NewsGuard 100/100 Score

Astra Tech, leading provider of comprehensive solutions for dental implant therapy, launched their OsseoSpeed™ TX implant line to the US market at this year’s AO Annual Meeting. The OsseoSpeed™ TX implant comes as the next step in the continuous evolution of the Astra Tech Implant System™ with its modified tapered apex design, first introduced with the launch of their narrow two-piece implant, OsseoSpeed™ TX 3.0 S in June 2008. This new design modification allows for easier implant installation in all indications, especially in soft bone where under-preparation is often desired.

“We are extremely pleased with the overwhelming, positive response to this new design modification, received during the AO Annual Meeting”

Ensuring optimal long-term esthetic results, all key features of the Astra Tech BioManagement Complex™, including OsseoSpeed™ fluoride-modified surface, MicroThread™ at the implant neck, a Conical Seal Design™ and the Connective Contour™ are maintained.

“We are extremely pleased with the overwhelming, positive response to this new design modification, received during the AO Annual Meeting,” states Scott Root, President and CEO, Astra Tech North America. “We are confident that this new modification will help to further simplify the implant treatment procedure for all our customers while still delivering the optimal results they’ve come to expect.”

Source:

Astra Tech AB

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global study reveals mismatch in COVID-19 treatment guidelines with WHO standards